Oncology market trends highlight growing competition around treatment positioning and patient selection, as therapies advance into earlier treatment settings, biomarker-defined strategies become more specific, and radiopharmaceutical competition expands across established and emerging approaches.
Coverage Period: 11 September – 15 October 2026
Introduction
The defining story of this reporting period was oncology competition moving toward more precisely selected patients and more strategically valuable positions in the treatment pathway. Biomarker-defined therapies advanced across breast, colorectal, lung and biliary cancers, while targeted therapy and immunotherapy continued to move into first-line, perioperative and adjuvant settings. At the same time, radiopharmaceutical oncology broadened in two directions: greater competition around established lutetium-177 therapy and clinical validation of next-generation alpha-emitting approaches. Together, these developments suggest that differentiation is increasingly being determined not simply by therapeutic modality, but by where, for whom and with what level of evidence a treatment can compete.
Companies covered: Revolution Medicines, AstraZeneca, Astellas Pharma, Roche, Eli Lilly, Elevar Therapeutics, AbbVie, Lantheus, Novartis, Bristol Myers Squibb, Theriva Biologics
Diseases covered: Pancreatic cancer / Metastatic pancreatic cancer, Muscle-invasive bladder cancer (MIBC), Colon cancer, Advanced breast cancer, ESR1-mutated advanced breast cancer, Cholangiocarcinoma, Colorectal cancer (CRC), Non-small cell lung cancer (NSCLC), Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Watch the video summary
Executive Summary
- Earlier treatment is becoming a major competitive battleground. RASONQUE is advancing toward first-line metastatic pancreatic cancer, while Imfinzi plus enfortumab vedotin is under Priority Review in perioperative muscle-invasive bladder cancer and Tecentriq has entered adjuvant stage III dMMR colon cancer.
- Biomarker-defined oncology is becoming more granular. ESR1-mutated breast cancer, FGFR2-altered cholangiocarcinoma and c-Met-expressing colorectal and lung cancers show how increasingly specific molecular or protein-defined populations are shaping development and regulatory strategies.
- Radiopharmaceutical competition is broadening beyond a single innovation model. BRAVNETSA introduced an ANDA-based competitor to established lutetium-177 therapy, while RYZ101 generated the first positive Phase 3 results for an alpha-emitting targeted radiopharmaceutical therapy.
- Combination approaches remain central in difficult-to-treat tumors. In pancreatic cancer, RAS inhibition and tumor-microenvironment modification are both being layered onto established gemcitabine/nab-paclitaxel chemotherapy rather than attempting to replace it outright.
Strategic Perspective on Four Recent Oncology Market Developments
Earlier-Line Oncology: Competition Moves Toward Higher-Value Treatment Settings
One of the clearest signals this period was the continued movement of differentiated therapies into earlier treatment positions.
Revolution Medicines received Breakthrough Therapy Designation for RASONQUE plus gemcitabine and nab-paclitaxel in treatment-naïve metastatic pancreatic adenocarcinoma. The designation was supported by Phase 1/2 data and has informed the ongoing global Phase 3 RASolute 303 study, which evaluates RASONQUE both as monotherapy and with chemotherapy in previously untreated disease.
In bladder cancer, AstraZeneca’s Imfinzi plus neoadjuvant enfortumab vedotin received Priority Review for patients with muscle-invasive disease who are ineligible for or have declined cisplatin. Positive Phase 3 VOLGA results showed improvements in event-free and overall survival, positioning the regimen for potential use in a curative-intent setting where treatment options remain limited.
Roche’s Tecentriq approval in stage III dMMR colon cancer reinforces the same shift. The ATOMIC study showed a 50% reduction in the risk of recurrence or death versus chemotherapy alone, establishing the first approved adjuvant immunotherapy regimen for this biomarker-defined population.
Market implication: Earlier positioning can expand addressable populations and allow successful therapies to influence subsequent treatment sequencing.
Key uncertainty: Adoption will depend on whether clinical gains justify additional toxicity, treatment burden and cost in settings where many patients may already be treated with curative intent.
Precision Oncology: Biomarker Selection Drives Competitive Differentiation
The period also showed how precision oncology is becoming increasingly specific in both patient selection and competitive positioning.
Lilly secured FDA approval for imlunestrant plus abemaciclib in ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy. In EMBER-3, the combination doubled median progression-free survival versus imlunestrant alone, reinforcing ESR1 mutation status as an actionable determinant of treatment choice.
Elevar advanced lirafugratinib toward European review for FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. Its strategy emphasizes selective FGFR2 inhibition rather than broader pan-FGFR blockade, while additional development is assessing whether the same biomarker can support expansion into other solid tumors.
AbbVie’s telisotuzumab adizutecan added a third example, receiving two Breakthrough Therapy Designations across colorectal cancer and non-small cell lung cancer. The c-Met-directed ADC is being positioned both as a combination therapy and as monotherapy in molecularly or protein-defined populations.
Market implication: Precision oncology competition is moving beyond identifying actionable biomarkers toward determining how narrowly therapies can define responsive populations while still supporting commercially meaningful use.
Key uncertainty: Greater segmentation increases dependence on diagnostic testing, biomarker prevalence and clear differentiation from therapies targeting overlapping populations.
Radiopharmaceutical Oncology: Competition Expands Across Access and Isotopes
Radiopharmaceuticals produced one of the strongest modality-level signals of the reporting period.
Lantheus received FDA approval for BRAVNETSA, a lutetium-177 dotatate product determined to be bioequivalent and therapeutically equivalent to LUTATHERA for SSTR-positive GEP-NETs. Importantly, BRAVNETSA was approved through the ANDA pathway, introducing a new form of competitive pressure around an established radioligand therapy rather than relying on a differentiated clinical mechanism.
At the same time, Bristol Myers Squibb’s RayzeBio reported positive interim Phase 3 ACTION-1 results for RYZ101, an actinium-225-targeted radiopharmaceutical, in patients whose GEP-NETs had progressed after lutetium-177 therapy. The trial demonstrated a statistically significant and clinically meaningful progression-free survival improvement and represents the first Phase 3 evidence for an alpha-based targeted radiopharmaceutical therapy.
This creates a potentially important strategic distinction. Competition in radiopharmaceuticals may now develop both within established isotopes, through access and economics, and between isotope generations, through attempts to extend efficacy after prior radioligand treatment.
Market implication: Radiopharmaceutical markets may increasingly resemble broader oncology markets, with differentiation based on sequencing, isotope selection, access and clinical evidence.
Key uncertainty: Manufacturing scale, isotope availability, treatment-center infrastructure and detailed efficacy and safety data will remain critical determinants of adoption.
Pancreatic Cancer: Novel Combinations Aim to Strengthen Chemotherapy
Pancreatic cancer developments illustrate another emerging competitive pattern: new mechanisms are being integrated with established chemotherapy rather than necessarily replacing it.
RASONQUE is being combined with gemcitabine and nab-paclitaxel as Revolution Medicines moves RAS inhibition toward untreated metastatic disease. Separately, Theriva is developing VCN-01, an oncolytic adenovirus designed to degrade tumor stroma and potentially enhance both drug penetration and immune activity.
Following Phase 2b VIRAGE results, Theriva initiated VIRAGE2 to assess whether more frequent repeated VCN-01 dosing with gemcitabine/nab-paclitaxel is feasible. The study is primarily designed to evaluate tolerability and pharmacodynamics rather than formally test clinical efficacy, with results intended to inform subsequent development.
Market implication: In tumors where established chemotherapy remains difficult to displace, competitive innovation may increasingly focus on improving its effectiveness through targeted inhibition or modification of the tumor microenvironment.
Key uncertainty: Larger controlled studies will need to show that added biological complexity translates into sufficiently durable clinical benefit.
What We Are Watching Next in Oncology Drug Development and Competition
- The FDA decision on Imfinzi plus enfortumab vedotin in cisplatin-ineligible muscle-invasive bladder cancer.
- Detailed ACTION-1 results and regulatory discussions for actinium-225 RYZ101.
- Phase 3 validation of first-line RASONQUE-based strategies in metastatic pancreatic cancer.
- Regulatory progression and broader tumor-agnostic development of lirafugratinib in FGFR2-altered cancers.
- Whether VIRAGE2 establishes a viable repeated-dosing regimen for VCN-01 that can support pivotal development.
Key Takeaway: Treatment Positioning and Patient Selection Reshape Oncology Competition
Oncology differentiation is becoming increasingly dependent on precision of positioning rather than modality alone. The strongest developments this period combined biomarker-defined patient selection, movement into earlier and more strategically valuable treatment settings, or technologies capable of extending established treatment pathways. Radiopharmaceuticals reflect the same shift from another direction, with competition developing simultaneously through greater access to existing therapy and next-generation isotope innovation. The next test will be whether this clinical and regulatory momentum translates into durable positions in increasingly segmented treatment markets.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com